The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1765-1772

  Kolesar, Jill M ^a,b   Dahlberg, Suzanne E ^c,d   Marsh, Sharon ^c   McLeod, Howard L ^e   Johnson, David H ^f,h   Keller, Steven M ^g   Schiller, Joan H ^h  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Lung cancer; NAD(P)H; p53; Polymorphism; Quinone oxidoreductase 1

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; ETOPOSIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); ANTINEOPLASTIC AGENT; NQO1 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIVIDUALIZATION; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; WILD TYPE; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; RADIOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79954496050     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1249     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Pisani P, Parkin DM and Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985. Int J Cancer 55: 891-903, 1993.
3. Keller SM, Adak S, Wagner H, et al: A randomized trial of post-operative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N Engl J Med 343: 1217-1222, 2000.
4. Rube C and Fleckenstein J: Combined-modality treatment of non-small cell lung cancer stages I-III (take home messages). Lung Cancer 45: S139-S141, 2004. (Pubitemid 39488183)
5. Belani CP: Adjuvant and neoadjuvant therapy in non-small cell lung cancer. Semin Oncol 32: S9-S15, 2005.
6. Bradley JD, Paulus R, Graham MV, et al: Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIa non-small cell lung cancer: promising long-term results of the radiation therapy oncology group-RTOG 9705. J Clin Oncol 23: 3480-3487, 2005.
7. Traver KD, Horikoshi T, Danenberg KD, et al: NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52: 797-802, 1992.
8. Ross D, Traver RD, Siegel D, et al: A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 74: 995-996, 1996. (Pubitemid 26319344)
9. Traver RD, Siegel D, Beall HD, et al: Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 75: 69-75, 1997. (Pubitemid 27007275)
10. Siegel D, McGuinness SM, Wnski SL, et al: Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9: 113-121, 1999. (Pubitemid 29176730)
11. Chao C, Zharg ZF, Berthiller J, Boffetta P and Hashibe M: NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev 5: 979-987, 2006.
12. Kiyohara C, Yoshimasu K, Takayama K and Nakanishi Y: NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 7: 463-478, 2005.
13. Dinkova-Kostova AT and Talalay P: NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 1: 116-123, 2010.
14. Song SY, Jeong SY, Park HJ, et al: Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer. Lung Cancer 2: 278-282, 2010.
15. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH and Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
16. Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L and Johnson DH: Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 19: 448-457, 2001. (Pubitemid 32112858)
17. Asher G, Lotem J, Sachs L, et al: Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci USA 99: 13125-13130, 2002.
18. Asher G, Lotem J, Kama R, et al: NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 99: 3099-3104, 2002. (Pubitemid 34240592)
19. Asher G, Lotem J, Cohen B, et al: Regulation of p53 stability and p53-dependent apoptosis by NADH quinine oxidoreductase 1. Proc Natl Acad Sci USA 98: 1188-1193, 2001. (Pubitemid 32121208)
20. Asher G, Tsvetkov P, Kahana C and Shaul Y: A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 19: 316-321, 2005. (Pubitemid 40189294)
21. Garate M, Wong RP, Campos EI, Wang Y and Li G: NAD(P)H quinone oxidoreductase 1 inhibits the proteasomal degradation of the tumour suppressor p33(ING1b). EMBO J 6: 576-581, 2008.
22. Tsutsumi K, Yasuda M and Nishioka T: X-ray irradiation altered chemosensitivity of a p53-null non-small cell lung cancer cell line. Cell Struct Funct 31: 47-52, 2006. (Pubitemid 46100427)
23. Lai SL, Perng RP and Hwang J: p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 7: 64-70, 2000.
24. Rusch V, Klimstra D, Venkatramen E, et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55: 5038-5042, 1995.
25. Tammemagi MC, McLaughlin JR and Bull SB: Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev 8: 625-634, 1999. (Pubitemid 29337324)
26. Mitsudomi T, Hamajima N, Ogawa M, et al: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6: 4055-4063, 2000.